Further large-scale trials, especially randomized controlled trials, with diverse study populations in terms of age and type of NSCLC, as well as a thorough review of all outcome measures are recommended, to more precisely compare binimetinib with other MEK inhibitors or targeted therapies and their cost-effectiveness, safety, and efficacy. Here, MAP2K7 is linked to non-small cell lung carcinoma.